Pricing Log in Create free account
Friday 6 November 2026 Export EVO’s income statement to Excel — free account

Evotec AG

EVO Healthcare Drug Manufacturers Specialty & Generic

Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024.

Revenue
−13.0%
EPS
−328.9%
Free cash flow
−9,727.2%
Total debt
+5.48%

Quarter to June 2026, against a year earlier

1.76 0.19 +12.10%
Market cap
$630.4M
P/E
0.0×
Fwd P/E
−2.2×
Dividend yield
—
F-score
5/9
Altman Z
0.64
Beneish M
−2.62
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 5.15%

Capital & Financial Ratios $m

Size
Market Cap 630.44
Revenue ttm 864.62
Net income ttm (227.93)
Free cash flow ttm (200.23)
Net debt Q 11.95
Valuation
P/E 0.00
Forward P/E (2.21) (negative: loss-making)
Price / sales 0.72
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.81
Financial health
Current ratio Q 2.33 (at or above 1.5: strong)
Debt / equity Q 0.72
Interest coverage Q (4.63)
Growth
Revenue growth Q −12.98% (below 0%: shrinking)
Operating income growth Q −574.06% (below 0%: shrinking)
EPS, this year −128.81% (below 0%: weak)
EPS, next year A +72.38% (at or above 15%: strong)
Revenue, next year A −10.49% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +84.05% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.7×, against a ten-year median of 5.1×; over the ten years it ranged from 0.6× in 2026 to 15.6× in 2017.
P/S against its own 10 years 1.47%
10-year low 10-year high
P/B against its own 10 years 1.47%
10-year low 10-year high
EV/Sales against its own 10 years 1.47%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2016–21
−100.0%/yr
  1. 0.17 ’16
  2. 0.14 ’17 −15
  3. 0.14 ’18 −6
  4. 0.02 ’19 −87
  5. 0.00 ’20 −100
  6. 0.00 ’21
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 654 429 539 541
Receivables 194 171 197 155
Inventory 33 34 33 45
Other 41 54 55 60
977 738 863 847
2023 2024 2025 Q'26
Payables 145 93 73 57
ST’ Debt — — 118 72
Other 340 267 209 219
503 373 416 363

Compound Annual Growth %

10y 5y 3y
Sales 20.19% 9.28% 4.05%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 16.05% 2.20% (9.71%)

EPS $

Mar Jun Sep Dec Year
’26 (0.40) — — — —
’25 (0.09) (0.14) (0.14) 0.04 (0.33)
’24 (0.06) (0.29) (0.12) (0.12) (0.60)
’23 — (0.05) (0.12) — (0.26)
’22 (0.23) (0.08) (0.13) (0.07) (0.52)
’21 0.19 0.22 0.48 (0.13) 0.77
’20 0.06 (0.04) 0.00 0.00 0.02
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 183 — — — —
’25 211 194 192 295 892
’24 227 196 203 236 862
’23 — 186 214 — 846
’22 185 183 175 249 792
’21 160 167 188 216 731
’20 132 123 151 166 572
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (125) — — —
’25 (34) 28 (79) 75 (10)
’24 (52) (54) 45 81 20
’23 — (6) 23 — 39
’22 71 185 (18) (24) 214
’21 3 47 23 72 145
’20 30 (38) 32 27 51
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (17) (137) — — —
’25 (56) (1) (106) 60 (104)
’24 (94) (96) 13 56 (121)
’23 — (120) (27) — (194)
’22 23 146 (89) (57) 23
’21 (41) 3 (7) 49 4
’20 12 (51) (1) (22) (62)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 182 291 443 500 572 731 792 846 862 892 865 +19.3% 798 962 1,046 +5.5%
Gross margin, % 35.59 32.05 29.84 29.77 25.10 24.52 23.16 22.40 14.41 14.49 11.42 (21.1) pt
EBT 36 30 85 63 29 280 (162) (87) (210) (98) (210) n/m
EBT margin, % 20.03 10.22 19.18 12.67 5.15 38.34 (20.49) (10.31) (24.34) (11.01) (24.26) (31.0) pt
Net income 30 27 99 42 7 255 (185) (91) (212) (117) (228) n/m
Per share, $
Per share, $ Revenue 0.69 1.00 1.50 1.67 1.86 2.20 2.24 2.39 2.43 2.51 2.43 +15.5%
Earnings 0.11 0.10 0.34 0.14 0.02 0.76 (0.52) (0.26) (0.60) (0.33) (0.64) n/m
Cash flow 0.28 0.04 0.63 0.16 0.17 0.43 0.61 0.11 0.06 (0.03) 0.00 n/m
Capex (0.04) (0.07) (0.11) (0.12) (0.37) (0.42) (0.54) (0.66) (0.40) (0.26) 0.00 +22.5%
Free cash flow 0.24 (0.02) 0.51 0.04 (0.20) 0.01 0.06 (0.55) (0.34) (0.29) 0.00 n/m
Book value 0.89 1.29 1.70 1.78 2.69 4.90 3.54 3.43 2.91 2.59 0.00 +12.6%
Shares, m 265 290 295 299 308 333 353 354 355 355 355 +3.3%
Valuation, ×
Valuation, × P/E 35.39 91.00 30.41 92.98 1,048.57 30.94 0.00 0.00 0.00 0.00 0.00 132.9
P/S 5.93 8.16 6.63 7.70 9.86 10.81 3.64 4.90 1.71 1.23 0.72 6.1
P/B 4.56 6.33 5.85 7.20 6.83 4.85 2.30 3.25 1.43 1.19 0.81 4.4
EV/Sales 5.33 8.54 6.53 7.98 9.85 10.23 3.34 4.28 1.90 1.19 0.74 5.9
EV/FCF 15.29 (355.12) 19.17 363.59 (89.05) 2,795.22 121.73 (11.96) (13.52) (10.25) (3.18) 283.5
Cash, $m
Cash, $m Operating cash flow 75 12 185 47 51 145 214 39 20 (10) (134) n/m
Capex (11) (19) (33) (36) (113) (141) (191) (233) (141) (93) (67) +26.5%
Free cash flow 63 (7) 152 12 (62) 4 23 (194) (121) (104) (200) n/m
Balance, $m
Balance, $m Working capital 106 (74) 63 325 514 919 775 475 365 447 484 +17.3%
Net debt (108) 111 (44) 144 (5) (426) (239) (137) (4) (31) 12 (12.9%)
Shareholders’ equity 237 375 502 534 826 1,630 1,251 1,212 1,031 921 774 +16.3%
Returns, %
Returns, % ROA 8.59 4.80 11.94 3.82 0.48 11.82 (7.37) (3.77) (9.41) (5.84) 0.00 (14.4) pt
ROIC 16.84 5.45 12.48 6.46 4.22 2.52 1.36 (2.99) (9.39) (4.47) 0.00 (21.3) pt
ROE 13.71 8.96 22.68 8.23 1.05 20.77 (12.85) (7.37) (18.92) (12.00) 0.00 (25.7) pt
People
People Employees 1,238 2,178 2,617 3,030 3,572 4,198 4,952 5,061 4,827 4,553 — +15.6%
Revenue/emp, $m 0.15 0.13 0.17 0.17 0.16 0.17 0.16 0.17 0.18 0.20 — +3.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Evotec AG vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COLL Collegium Pharmaceutical, Inc. $819.1M 20.5× 21.3× +3.33% (above 0%: growing) −31.00% (below 0%: shrinking) +10.24% (above 0%: growing) 57.97% 13.28% Compare
IRWD Ironwood Pharmaceuticals, Inc. $665.9M 4.3× 2.9× +9.00% (above 0%: growing) +44.00% (above 0%: growing) +41.66% (above 0%: growing) 100.00% 70.00% Compare
EVO Evotec AG $630.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%)
TKNO Alpha Teknova, Inc. $486.2M — (loss-making) — (loss-making) +21.52% (above 0%: growing) n/m +40.94% (above 0%: growing) 37.99% (25.24%) Compare
AQST Aquestive Therapeutics, Inc. $460.0M — (loss-making) — (loss-making) −40.99% (below 0%: shrinking) n/m +40.78% (above 0%: growing) 52.28% (191.46%) Compare
EOLS Evolus, Inc. $448.8M — (loss-making) — (loss-making) +13.03% (above 0%: growing) n/m +77.73% (above 0%: growing) 65.02% (10.81%) Compare
TLRY Tilray Brands, Inc. $415.3M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −159.66% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $396.3M 18.1× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32% Compare
ACB Aurora Cannabis Inc. $341.2M — (loss-making) — (loss-making) −31.15% (below 0%: shrinking) n/m −293.56% (below 0%: shrinking) 52.73% (12.92%) Compare
Median of peers $454.4M 18.1× — +11.02% +23.08% +40.86% 52.51% (10.08%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Evotec AG (EVO) Latest News

5 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · PR Newswire

29 Oct

Impact 4 · · PR Newswire

25 Oct

Impact 4 · · Simply Wall St.

15 Oct

Impact 4 · · PR Newswire

14 Oct

Impact 3 · · Investing.com

29 Sep

Impact 3 · · PR Newswire
Impact 3 · · GlobeNewswire

9 Sep

Impact 4 ·

2 Sep

Impact 3 ·

7 Aug

Impact 3 · · pharmaceutical-technology.com

6 Aug

Impact 3 ·

3 Aug

Impact 3 ·

14 Jul

Impact 3 ·
Impact 3 · · MarketBeat transcript

13 Jul

Impact 4 ·

30 Jun

Impact 3 ·

2 Jun

Impact 3 · · ACCESS Newswire

13 May

Impact 3 · · Insider Monkey

12 May

Impact 4 · · ACCESS Newswire

6 May

Impact 3 · · MarketBeat

5 May

Impact 3 · · Simply Wall St.

4 May

Impact 3 · · ACCESS Newswire

30 Apr

Impact 3 · · ACCESS Newswire

24 Apr

Impact 3 · · ACCESS Newswire

15 Apr

Impact 3 · · ACCESS Newswire

14 Apr

Impact 4 · · Insider Monkey

8 Apr

Impact 4 · · The Motley Fool transcript
stockrow.com/EVO · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com